Evidence map›Paper›PMID 39070095›Full record

ArticleMaterials today. Bio2024

An intratumor bacteria-targeted DNA nanocarrier for multifaceted tumor microenvironment intervention.

Yibiao Wang, Xiaomei Fu, Yang Zhu, Mingjing Lin, Renduan Cai, Yang Zhu, Tiantian Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Artificial cell vesicle-mediated delivery ofFrontiers in bioengineering and biotechnology · 2025
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yibiao WangDepartment of Neurosurgery/Department of Pediatrics/Department of Neonatal, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, 570311, China.
Xiaomei FuDepartment of Neurosurgery/Department of Pediatrics/Department of Neonatal, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, 570311, China.
Yang ZhuDepartment of Neurosurgery/Department of Pediatrics/Department of Neonatal, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, 570311, China.
Mingjing LinDepartment of Neurosurgery/Department of Pediatrics/Department of Neonatal, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, 570311, China.
Renduan CaiDepartment of Neurosurgery/Department of Pediatrics/Department of Neonatal, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, 570311, China.
Yang ZhuFujian Provincial Institutes of Brain Disorders and Brain Sciences/Department of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, Fujian, China.
Tiantian WuSchool of Pharmacy, Hainan Medical University, Haikou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intratumor bacteria, which are involved with complex tumor development mechanisms, can compromise the therapeutic efficiencies of cancer chemotherapeutics. Therefore, the development of anti-tumor agents targeting intratumor bacteria is crucial in overcoming the drug inactivation induced by bacteria colonization. In this study, a double-bundle DNA tetrahedron-based nanocarrier is developed for intratumor bacteria-targeted berberine (Ber) delivery. The combination of aptamer modification and high drug loading efficacy endow the DNA nanocarrier TA@B with enhanced delivery performance in anti-tumor therapy without obvious systemic toxicity. The loaded natural isoquinoline alkaloid Ber exhibits enhanced antimicrobial, anticancer, and immune microenvironment regulation effects, ultimately leading to efficient inhibition of tumor proliferation. This intratumor bacteria-targeted DNA nanoplatform provides a promising strategy in intervening the bacteria-related microenvironment and facilitating tumor therapy.

Indexed as

BerberineDNA self-assemblyIntratumor bacteriaTargeted deliveryTumor microenvironment

Identifiers

PMID39070095
PMCPMC11279327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.